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Controlling the pulmonary vascular bed is key
to the early management of infants with congenital
heart disease (CHD) who have potential for exces-
sive pulmonary blood flow or obstruction to blood
egress from the lungs. Timing of surgical manage-
ment has evolved to ensure that the hemodynamic
consequences of excessive pulmonary blood flow or
pulmonary venous hypertension do not translate
into irreversible elevation of pulmonary vascular
resistance through remodeling of the pulmonary
vascular bed, characterized by smooth muscle cell
hypertrophy, pulmonary vasoconstriction and im-
paired endothelium-dependent pulmonary vasodi-
lation. However, even with appropriately timed
surgery, the pulmonary vascular bed remains reac-
tive to cardiopulmonary bypass, which precipitates
activation of a systemic inflammatory response with
associated endothelial cell injury and inhibition of
nitric oxide (NO) production and increase in endo-
thelin levels [1]. The post-operative response may
vary from clinically irrelevant elevation in right
ventricular pressures to pulmonary hypertensive
(PH) crises characterized by abrupt pulmonary vas-
oconstriction leading to hypotension, hypoxia and
associated with increased mortality [2]. High-risk
pre-operative anatomic subtypes as well as preven-
tative post-operative strategies for those at risk
have been defined [2], and as a consequence the
incidence of PH crises have declined significantly
from over 30% in the 1980’s to less than 1% in con-
temporary series [3], although this may vary de-
pending on the definitions and treatment protocols
used. Mortality, however associated with severe
post-operative PH remains high at approximately
10% [3]. Inhaled NO (iNO), mediates selective pul-
monary vasodilation by stimulating production of
cGMP and both retrospective [4], and randomized
trials [5] have demonstrated fewer post-operative
pulmonary hypertensive crises and significant de-
creases in mortality, although these results have
not been substantiated by a systematic review [6].
Nearly all studies however have demonstrated ef-
ficacy in reducing elevated pulmonary artery pres-
sures in the post-operative infant undergoing sur-
gery for CHD and consequently iNO has become
the standard therapy for post-operative PH in this
setting. Timing of introduction of iNO may vary
between institutions with some employing an ear-
ly post-operative “prophylactic” approach in those
at risk and others reserving iNO for those with prov-
en severe post-operative PH. Concerns have been
raised however regarding potential for oxidation of
hemoglobin to methemoglobin by iNO. This may
lead to reduced oxygen carrying capacity of hemo-
globin as methemoglobin in unable to reversibly
bind oxygen and levels over 10% in infants have
been associated with cyanosis. Rebound PH has also
been described with rapid weaning due to a down-
regulation of endogenous NO production [7]. For
these reasons comparable alternative therapies for
PH in the post-operative CHD patient have been
sought. Iloprost is an analog of prostacyclin, which
through a cAMP dependent pathway leads to de-
creased levels of cytosolic calcium and selective
pulmonary vasorelaxation. Previous studies assess-
ing iloprost in CHD patients with post-operative PH
have demonstrated effective reduction in mean
336
Cardiology Journal 2012, Vol. 19, No. 4
www.cardiologyjournal.org
pulmonary artery pressures [8], however previous
comparative studies with iNO have not suggested
superior efficacy of one agent over the other in re-
ducing post-operative pulmonary pressures [9, 10].
In this edition of the journal, Kirbas et al. [11],
report on the randomized use of iNO versus nebu-
lized iloprost in 16 children (mean age of 36 months)
with severe PH undergoing intracardiac repair of
CHD. All patients were deemed to have PH as de-
fined by pulmonary artery to aortic pressure ratios
> 0.7 although it is not clear whether this defini-
tion was applied pre- or post-operatively. Only pa-
tients > 24 months underwent pre-operative ca-
theterization and indexed pulmonary resistances
were not reported. Both agents were commenced
immediately after cardiopulmonary bypass. iNO was
administered at 20 parts per million with nebulized
iloprost dosage of 0.5 mg/kg every 90 min mirror-
ing doses used in previous studies [10]. In similar
cohorts of patients both agents produced significant
reductions in pulmonary artery pressures and pul-
monary artery to systemic pressure ratios over the
3 days of monitoring. Cardiac output increased sig-
nificantly in both groups but mirroring previous
studies, superior efficacy of either agent over the
other was not demonstrated with respect to any of
the measured variables. No PH crises were report-
ed in either group with no significant adverse ef-
fects seen in either cohort.
This study confirms previous reports suggest-
ing comparable efficacy of both agents in treating
post-operative PH. The paper provides a template
on how to identify and approach high-risk patients,
and highlights optimal peri- and post-operative
strategies to limit the impact of cardiac surgery on
the pulmonary vascular bed. Both filling pressures
and pulmonary arterial and systemic pressures
should be continuously monitored to herald acute
elevations in pulmonary vascular resistance so that
pulmonary hypertensive crises may be dealt with
quickly. As to which agent should be used, we are
probably no wiser than before and it appears to come
down to a matter of choice. Both agents are deli-
vered locally with less systemic effects than intra-
venous agents. It is true that iNO requires a some-
what complicated delivery system, however many
units have mastered this technique and it may be
that the optimal approach is the one that is estab-
lished. Certainly switching from one agent to an-
other without a clear understanding of dosing and
delivery is not advised. Both agents may be used
simultaneously however this has not demonstrat-
ed increased potency over either substance alone
[9]. Other issues relating to cost are not to be un-
derestimated with reports suggesting daily admini-
stration of iNO is 20 times more expensive than
inhaled iloprost [8]. In a unit performing 300 open-
heart surgeries a year, with 5% of these patients
deemed to be high-risk requiring an average of
3 days post-operative therapy, this would equate
to an extra 100,000 USD per annum! Other issues
relating to potential risks with iNO including me-
themoglobinemia, and rebound PH as discussed
above also need to be considered. Issues plaguing
iloprost use in idiopathic pulmonary arterial hyper-
tension such as inconvenient dosing schedules and
potential for bronchoconstriction are not relevant
to the acute care of intubated post-operative chil-
dren. And so we are left with a choice based not on
efficacy but on cost and convenience. If further larg-
er studies corroborate the existing data, it may be
hard to justify the extra cost involved in persisting
with iNO.
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